Healthcare & Life Sciences updates

Sweden

Contributed by Westerberg & Partners Advokatbyrå Ab
Objective necessity to rebox in parallel trade and implementation of EU Falsified Medicines Regulation
  • Sweden
  • 16 September 2020

In a recent case, the Patent and Market Court (PMC) elaborated on the concept of objective necessity to rebox medicinal products subject to parallel distribution in light of the implementation of the EU Falsified Medicines Regulation. The PMC's decision is a significant victory for originators, as it confirms that relabelling is still the main rule in Sweden and that reboxing remains the exception and requires evidentiary support of objective necessity by the parallel trader.


Current search